Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
- New offices in Chile and Peru, expansion of Argentina office increase
access to patients to reduce drug development timelines for biopharmaceutical
PRINCETON, N.J., April 7 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE:
CVD) today announced the recent opening of new clinical development offices in
Santiago, Chile, and Lima, Peru, and the expansion of the company's Buenos
Aires, Argentina office. These latest office openings further extend the
company's global clinical development presence to increase patient access and
reduce clinical development timelines.
Covance has been providing clinical trial support in Latin America since
1997 with the company's first office in Buenos Aires, Argentina. Operations in
Latin America expanded quickly with the organization of an extensive and
highly-trained network of regional clinical trial monitors. The new clinical
offices located in Santiago and Lima will support staff in Chile and Peru,
including Covance's regional network of field-based clinical research
associates throughout Latin America.
"Our strategy is to target areas for qualified patient populations and the
most qualified investigators as we selectively expand our presence in key
metropolitan centers in emerging regions such as Latin America," said Katie
Margules, Covance's senior director of project management in Latin America.
"Our focus continues to be on delivering outstanding drug development and
building stronger strategic relationships with our clients."
The new offices and expanded facilities in Latin America will help Covance
expedite the execution of clinical studies with a full range of services, and
build strategic relationships with investigators, sites, and regulatory
authorities in a region known for its strong potential to contribute to
high-quality global clinical trial conduct.
"We are committed to continuing to build our infrastructure across Latin
America, expanding current facilities, and opening further new clinical
offices to increase Phase III clinical trial productivity," said Wayne
Langlois, Covance's vice president and general manager of clinical development
services, Americas. "These countries offer qualified patient populations and
investigators which help reduce clinical development timelines for our
Covance offers clinical development services, including Phase I to IV
clinical trial support in more than 55 countries which include emerging
markets across Asia Pacific, Central and Eastern Europe, and Latin America.
With a full-suite of services to take a drug through all stages of drug
development, Covance offers extensive clinical and therapeutic expertise,
global reach, proactive project management, and strong investigator site
relationships to consistently deliver high quality data on time.
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.5 billion, global operations in more than 25
countries, and more than 9,600 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.
Statements contained in this press release, which are not historical
facts, are forward-looking statements pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All such
forward-looking statements including the statements contained herein regarding
anticipated trends in the Company's business are based largely on management's
expectations and are subject to and qualified by risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the Company's
ability to continue to attract and retain qualified personnel, the fixed price
nature of contracts or the loss of large contracts, and other factors
described in the Company's filings with the Securities and Exchange